• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

More severe symptoms and hospitalizations seen during period of COVID-19 delta variant dominance compared to omicron

byJessie WillisandTeddy Guo
May 4, 2022
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Loss of sense of smell was more common during a period of delta dominance, while sore throat was more common during a period of omicron dominance.

2. Hospitalizations were more common among COVID-positive patients during the period of delta variant dominance.

Evidence Rating Level: 2 (Good)

Study Rundown: Two major variants of COVID-19 struck the UK at two distinct time periods. However, few studies have compared the differences in symptomatology between COVID-19 infections of different variants. This study aimed to characterize the differences between the two variants, Delta (B.1.617.2) and Omicron (B.1.1.529), by using a self-reporting application for participants. A total of 63002 app users tested positive and submitted symptoms. After separating participants depending on whether delta or omicron was more prevalent when they tested positive, participants were matched 1:1 based on age, sex and vaccination dose. Loss of sense of smell was significantly more common in the delta group while sore throat was more common in the omicron group. Hospitalization was also more prevalent in the delta group, with a greater median number of symptoms overall. Limitations of this study include the self-reported nature of the data and the lack of confirmation of the variant each participant had. Nonetheless, this study demonstrated that less severe symptoms were present during the omicron wave compared to the delta wave in the UK. It also successfully employed an application to track symptoms which could be used for future variants.

Click to read the study in The Lancet.

Relevant Reading: Increased immune escape of the new SARS-CoV-2 variant of concern Omicron

In-Depth [prospective observational study]: The ZOE COVID Study collected and analyzed self-reported health information via app. Eligibility criteria included participants aged 16-99 years and who had received two doses of any COVID vaccine. Patients needed to be symptomatic and required a positive PCR or LFAT test. A total of 63,002 application users tested positive and reported symptoms. The study used two distinct time periods of either delta prevalence (June 1 to Nov 27, 2021) or omicron prevalence (Dec 20, 2021, to Jan 17, 2022). Patients in each variant group were matched 1:1 for age, sex, and vaccination dose. After 1:1 matching, the number of participants in each variant group was 4990.

RELATED REPORTS

Unvaccinated status increases risk of long COVID symptoms

The Scan by 2 Minute Medicine®: The Fight Against Childhood Obesity, Prioritizing Mental Health, The Rise of XBB1.5, and Choose Your Chocolates Wisely

Combined visual-olfactory training for COVID-19 resultant olfactory loss

The most frequent symptoms reported during delta dominance were runny nose (81.6%), headache (77.9%), sneezing (70.7%), sore throat (60.8%), and loss of smell (52.7%). The most frequent symptoms reported during omicron dominance were runny nose (76.5%), headache (74.7%), sore throat (70.5%), sneezing (63.0%), persistent cough (49.8%), and hoarse voice (42.6%). There was a greater median number of symptoms in the delta prevalent group. The study calculated odds ratios for each symptom for the omicron versus delta group. Significant differences were seen in loss of smell (OR 0.17, 95% CI 0.16-0.19, p<0.001) and sore throat (OR 1.55, 1.43-1.69, p<0.001). The hospital admission rate was also less for omicron versus delta (OR 0.75, 0.57-0.98, p=0.03). Overall, patients infected during the omicron-dominant period were less likely to report at least one of the classical COVID-19 symptoms of fever, persistent cough, and loss of smell, compared to those infected during delta-dominant periods (OR 0.56, 95% CI 0.51-0.61; p<0.001).

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: CoronavirusCOVID-19Delta variantOmicron variantSARS-CoV-2
Previous Post

The ACCORD trial: Intensive glucose control associated with increased mortality [Classics Series]

Next Post

#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia

RelatedReports

Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Unvaccinated status increases risk of long COVID symptoms

January 25, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Fight Against Childhood Obesity, Prioritizing Mental Health, The Rise of XBB1.5, and Choose Your Chocolates Wisely

January 25, 2023
School nurses essential in design and implementation of school safety programs
Chronic Disease

Combined visual-olfactory training for COVID-19 resultant olfactory loss

January 23, 2023
Many new pediatric asthma cases attributable to obesity
Weekly Rewinds

2 Minute Medicine Rewind January 23, 2023

January 23, 2023
Next Post
#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia

#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia

Provision of medically-tailored meals linked with lower admissions and medical spending

Wellness Check: Nutrition

Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation

Adequate sleep may reduce energy intake and weight in overweight adults

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options